Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juan Politei

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
JIMD Reports|February 23, 2013
Utility of rare disease registries in latin americaAna Maria Martins, Marcelo Kerstenezky, Adriana Linares, et al.
Molecular Genetics and Metabolism Reports|November 9, 2020
Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotypeRobert J Hopkin, Ulla Feldt-Rasmussen, Dominique P Germain, et al.
Molecular Genetics and Metabolism|March 14, 2018
Fabry disease revisited: Management and treatment recommendations for adult patientsAlberto Ortiz, Dominique P Germain, Robert J Desnick, et al.
Clinical Kidney Journal|February 13, 2019
Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytesHernán Trimarchi, Romina Canzonieri, Cristian Costales-Collaguazo, et al.
Journal of Nephrology|February 5, 2016
Podocyturia is significantly elevated in untreated vs treated Fabry adult patientsHernán Trimarchi, Romina Canzonieri, Amalia Schiel, et al.
Frontiers in Medicine|September 20, 2023
Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi studyDaniel G Bichet, Robert J Hopkin, Patrício Aguiar, et al.
Medicina|December 12, 2024
[Monogenic obesity: pathophysiology, diagnosis and treatment]María E Andrés, Marisa Armeno, Elizabeth Alonso, et al.
Molecular Genetics and Metabolism Reports|March 7, 2020
Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: Recommendations for distinct scenarios in Latin AmericaMarthaL Solano, Alejandro Fainboim, Juan Politei, et al.
International Journal of Nephrology|May 20, 2017
Expression of uPAR in Urinary Podocytes of Patients with Fabry DiseaseHernán Trimarchi, Romina Canzonieri, Amalia Schiel, et al.
Molecular Genetics and Metabolism Reports|April 25, 2025
Expert review in diagnostic, therapeutic and follow-up of Fabry disease in Latin America based on patient care standardsRoberto Giugliani, Juan Politei, Ana Martins, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
JIMD Reports|February 23, 2013
Utility of rare disease registries in latin americaAna Maria Martins, Marcelo Kerstenezky, Adriana Linares, et al.
Molecular Genetics and Metabolism Reports|November 9, 2020
Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotypeRobert J Hopkin, Ulla Feldt-Rasmussen, Dominique P Germain, et al.
Molecular Genetics and Metabolism|March 14, 2018
Fabry disease revisited: Management and treatment recommendations for adult patientsAlberto Ortiz, Dominique P Germain, Robert J Desnick, et al.
Clinical Kidney Journal|February 13, 2019
Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytesHernán Trimarchi, Romina Canzonieri, Cristian Costales-Collaguazo, et al.
Journal of Nephrology|February 5, 2016
Podocyturia is significantly elevated in untreated vs treated Fabry adult patientsHernán Trimarchi, Romina Canzonieri, Amalia Schiel, et al.
Frontiers in Medicine|September 20, 2023
Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi studyDaniel G Bichet, Robert J Hopkin, Patrício Aguiar, et al.
Medicina|December 12, 2024
[Monogenic obesity: pathophysiology, diagnosis and treatment]María E Andrés, Marisa Armeno, Elizabeth Alonso, et al.
Molecular Genetics and Metabolism Reports|March 7, 2020
Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: Recommendations for distinct scenarios in Latin AmericaMarthaL Solano, Alejandro Fainboim, Juan Politei, et al.
International Journal of Nephrology|May 20, 2017
Expression of uPAR in Urinary Podocytes of Patients with Fabry DiseaseHernán Trimarchi, Romina Canzonieri, Amalia Schiel, et al.
Molecular Genetics and Metabolism Reports|April 25, 2025
Expert review in diagnostic, therapeutic and follow-up of Fabry disease in Latin America based on patient care standardsRoberto Giugliani, Juan Politei, Ana Martins, et al.
Pageof 4